Subj: Corporate Profile for Ribozyme Pharmaceuticals Inc.,...
Date: 9/3/99 7:16:44 AM Pacific Daylight Time
Corporate Profile for Ribozyme Pharmaceuticals Inc., dated Sept. 3, 1999
--(BUSINESS WIRE)--The following Corporate Profile is available
for inclusion in your files. News releases for this client are
distributed by Business Wire and also become part of the leading
databases and online services, including all of the leading
Internet-based services.
-0-
Published Date: Sept. 3, 1999
Company Name: Ribozyme Pharmaceuticals Inc.
Address: 2950 Wilderness Place
Boulder, Colo. 80301
Main Telephone
Number: 303/449-6500
Internet Home
Page Address
(URL) www.rpi.com
Chief Executive
Officer: Ralph E. Christoffersen, Ph.D.
Chief Financial
Officer: Lawrence E. Bullock
Investor Relations
Contact: Alene A. Holzman
Business number: 303/546-8111
E-mail address: holzmaaa@rpi.com
Public Relations
Contact: Freeman McCue
Business number: 714/557-3663
E-mail address: prarus@aol.com
Industry: Biotechnology/Pharmaceuticals
Trading Symbol/
Exchange: NASDAQ/RZYM
Market Makers: Hambrecht & Quist
Company description: Ribozyme Pharmaceuticals Inc. (RPI) is
developing a new class of drugs based on "ribozymes," a form of
ribonucleic acid which has the ability to inhibit protein production.
RPI is collaborating with Chiron Corp. for commercialization of
ANGIOZYME, a drug for the treatment of solid-tumor cancers, such as
breast, prostate, colon, and rectum. This drug, which recently
completed successful human clinical trials for Phase Ia and Ib, has
large market potential: Some 750,000 new cancer cases are discovered
each year, and some 200,000 persons die each year from these cancers
in the U.S. alone. RPI is collaborating with Eli Lilly and Company to
commercialize HEPTAZYME, a drug treatment for Hepatitis C, the most
common blood-borne infection in the U.S., infecting some 50,000
Americans each year. Existing therapiesare ineffective in about 50% of
cases and have severe side effects.
In addition, RPI has other drugs in the pipeline,with 104 patents
issued and another 100 pending.
The company's business strategy includes:
-- aggressively developing Angiozyme & Heptazyme
-- identify and develop new product candidates to exploit the
broad potential of ribozymes
-- partner with others to develop products
-- license technology in areas RPI will not pursue
Recent stock price: $5.25; Market Cap: $58 million
CONTACT:
Ribozyme Pharmaceuticals Inc. |
